Evidence map›Paper›PMID 35565386›Full record

ReviewCancers2022

Xavier Cansouline, Béatrice Lipan, Damien Sizaret, Anne Tallet, Christophe Vandier, Delphine Carmier, Antoine Legras

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Insights intoCancers · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xavier CansoulineDepartment of Thoracic Surgery, Tours University Hospital, 37170 Chambray-Lès-Tours, France.
Béatrice LipanDepartment of Thoracic Surgery, Tours University Hospital, 37170 Chambray-Lès-Tours, France.
Damien SizaretDepartment of Pathology, Tours University Hospital, 37170 Chambray-Lès-Tours, France.
Anne TalletPlatform of Solid Tumor Molecular Genetics, Tours University, 37000 Tours, France.
Christophe VandierNutrition, Croissance et Cancer, INSERM UMR 1069, University of Tours, 37000 Tours, France.ORCID 0000-0003-2559-0660
Delphine CarmierDepartment of Pneumology, Tours University Hospital, 37000 Tours, France.
Antoine LegrasDepartment of Thoracic Surgery, Tours University Hospital, 37170 Chambray-Lès-Tours, France.ORCID 0000-0002-5271-6946
Université de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ADAURA trial has been significant for the perception of

Indexed as

ADAURAadjuvantchemotherapyearly stagesEGFRneoadjuvantNSCLCresected lung cancertargeted therapytyrosine kinase inhibitors

Identifiers

PMID35565386
PMCPMC9099844
OpenAlexW4225253315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.